title: Phase II study of cystemustine in metastatic colorectal carcinoma. A trial of the EORTC Clinical Screening Group.
abstract: 27 patients with metastatic colorectal carcinoma were treated, every 2 weeks, with 60 mg/m2 cystemustine, a new chloro-2-ethyl nitrosourea derivative. Haematological toxicity was the major side-effect including neutropenia and thrombocytopenia. We did not observe any complete or partial response. Cystemustine, with this dose and this schedule, has no activity in colorectal cancer.
authors.affiliation: Centre Eugène Marquis, Rennes, France.
authors.forename: P
authors.initials: P
authors.lastname: Kerbrat
authors.forename: A
authors.initials: A
authors.lastname: Adenis
authors.forename: P
authors.initials: P
authors.lastname: Rebattu
authors.forename: H
authors.initials: H
authors.lastname: Roche
authors.forename: B
authors.initials: B
authors.lastname: Chevallier
authors.forename: P
authors.initials: P
authors.lastname: Chollet
authors.forename: I
authors.initials: I
authors.lastname: Krakowski
authors.forename: M A
authors.initials: MA
authors.lastname: Lentz
authors.forename: P
authors.initials: P
authors.lastname: Fumoleau
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced; D009607:Nitrosourea Compounds / Q000627:therapeutic use*; D013921:Thrombocytopenia / Q000139:chemically induced; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D009607:Nitrosourea Compounds; C051263:N'-(2-chloroethyl)-N-(2-(methylsulfonyl)ethyl)-N'-nitrosourea